Navigation Links
MINRAD International, Inc. Announces $40.0 Million Private Placement
Date:5/5/2008

Officer

ctrego@minrad.com

(716) 855-1068

http://www.minrad.com

About the Company

MINRAD International, Inc. is an interventional pain management company with real-time image guidance, anesthesia and analgesia, conscious sedation product lines. The real-time image guidance products facilitate minimally invasive surgery especially for pain management and have broad applications in orthopedics, neurosurgery, and interventional radiology. These devices enable medical professionals to improve the accuracy of interventional procedures and reduce radiation exposure. MINRAD International also manufactures and markets generic inhalation anesthetics for use in connection with human and veterinary surgical procedures. The company is developing a drug/drug delivery system for conscious sedation, which, similar to nitrous oxide in dental surgery, provides a patient with pain relief without loss of consciousness. Additional information can be found at the company's website, http://www.minrad.com.

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Factors that may cause actual results to differ materially from those expressed or implied by its forward-looking statements include, but are not limited to, Minrad International's limited operating history and business development associated with being a growth stage company; its dependence on key personnel; its need to attract and retain technical and managerial personnel; its ability to execute its business strategy; the intense competitio
'/>"/>

SOURCE MINRAD International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer
2. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
3. JPMorgans Principal Investment Management Group to Invest in Chindex International, Inc.
4. Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
5. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
6. Chindex International, Inc. to Present at 2008 UBS Global Healthcare Services Conference
7. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
8. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
9. VWR International, LLC Acquires Jencons (Scientific) Ltd, UK
10. Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses
11. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical ... that the Company closed its previously announced private ... Jack W. Schuler , Birchview Fund LLC and ... before offering expenses.  The proceeds will be used ... Under the terms of the private placement, ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... series is designed to introduce cutting edge ... users and partners of platform upgrades. This ... benefits; empowering users in their quest to ... tools. , According to SoundConnect’s Marketing Manager, ...
(Date:12/24/2014)... The report expects global cell isolation and ... also provides a carefully analyzed data about the vital ... market. , Full Copy of Report @ http://bit.ly/1yUxy0T ... for cell expansion will keep witnessing growth at an ... to be driven by rapid technological advancements, government funding ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
... ATLANTA, April 4, 2011 CryoLife, Inc. (NYSE: ... processing company, announced today that it has filed ... (FDA) to begin clinical trials for the purpose of obtaining ... control bleeding during surgical procedures or following traumatic injuries. ...
... ORLEANS, April 4, 2011 Orexigen ® ... additional data that showed that overweight and obese ... SR) maintained normal 24-hour circadian patterns over one ... ambulatory blood pressure monitoring (ABPM) sub-study of the ...
... (NASDAQ: OMER ), a biopharmaceutical company committed ... bleeding and disorders of the central nervous system, today ... executive officer, is scheduled to present at the 10th ... City this week.  The presentation is scheduled for Tuesday, ...
Cached Biology Technology:CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 2CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 3CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 4Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 2Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 3Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 4
(Date:12/22/2014)... Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... security consultant, Apollo Robbins for the 2015 ... Apollo Robbins will be ... , 2015, demonstrating some of his famous theft techniques ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics ... pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred ... has served as a meeting place for peoples from ... the ongoing mixing of peoples with African, European, and ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... and FRAMINGHAM, Mass. , Feb. ... and TruTouch Technologies, Inc. today announced that they have signed ... biometric test in the US.  The workplace sobriety assurance solution ... quickly and accurately measures alcohol consumption. This is simply done ...
... in the H5N1 avian influenza virus that affects the pH ... its capacity to infect ducks and enhances its capacity to ... today in the Journal of Virology . ... of a virus in one host species, tissue, or cell ...
... 2013 -- A range of new and promising targeted ... be presented during the 11th International Congress on Targeted ... event, which is organised by NDDO Education Foundation, is ... Cancer Institute. Over 500 oncologists and scientists ...
Cached Biology News:Psychemedics & TruTouch Announce US Sales/Marketing Distribution Agreement For TruTouch Technologies' Rapid Optical Alcohol Detection & Biometric Test 2Psychemedics & TruTouch Announce US Sales/Marketing Distribution Agreement For TruTouch Technologies' Rapid Optical Alcohol Detection & Biometric Test 3Psychemedics & TruTouch Announce US Sales/Marketing Distribution Agreement For TruTouch Technologies' Rapid Optical Alcohol Detection & Biometric Test 4Mutation altering stability of surface molecule in acid enables H5N1 infection of mammals 2Mutation altering stability of surface molecule in acid enables H5N1 infection of mammals 311th International Congress on Targeted Anticancer Therapies 2
... D kit is an enzymeimmunoassay intended ... D (25-OH D) and other hydroxylated ... Our patented DIRECT assay technology eliminates ... centrifugation and therefore facilitates automation on ...
... A multi-purpose, high gel-strength agarose suitable ... techniques, from conventional constant field to Pulsed ... high gel strength and exclusion limits, Multi ... with reduced running times. This in turn ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Rabbit polyclonal to L Kynurenine ( Abpromise for all tested applications). Antigen: Synthetic peptide L Kynurenine conjugated to a protein carrier. Entrez Gene ID: 8942 Swiss Protein ID...
Biology Products: